메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 28, Issue 1, 2010, Pages
What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma?
Author keywords

[No Author keywords available]
Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT;
EID: 73949156936     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.3293     Document Type: Letter
Times cited : (37)
References (6)
  • 1
    • 0033013787 scopus 로고    scopus 로고
    • Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rick classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease
    • Diehl V, Sextro M, Franklin J, et al: Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rick classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17:776-783, 1999
    • (1999) J Clin Oncol , vol.17 , pp. 776-783
    • Diehl, V.1    Sextro, M.2    Franklin, J.3
  • 2
    • 0026439199 scopus 로고
    • Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
    • Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
    • (1992) N Engl J Med , vol.327 , pp. 1478-1484
    • Canellos, G.P.1    Anderson, J.R.2    Propert, K.J.3
  • 3
    • 0037441857 scopus 로고    scopus 로고
    • Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an Intergroup trial
    • Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an Intergroup trial. J Clin Oncol 21:607-614, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 607-614
    • Duggan, D.B.1    Petroni, G.R.2    Johnson, J.L.3
  • 4
    • 0344837929 scopus 로고    scopus 로고
    • Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up
    • Canellos GP, Golub J, Neuberg D, et al: Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 14:268-272, 2003
    • (2003) Ann Oncol , vol.14 , pp. 268-272
    • Canellos, G.P.1    Golub, J.2    Neuberg, D.3
  • 5
    • 0030747027 scopus 로고    scopus 로고
    • Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease
    • Bodis S, Kraus MD, Pinkus G, et al: Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 15:3060-3066, 1997
    • (1997) J Clin Oncol , vol.15 , pp. 3060-3066
    • Bodis, S.1    Kraus, M.D.2    Pinkus, G.3
  • 6
    • 38049162295 scopus 로고    scopus 로고
    • Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Study Group
    • Schulz H, Rehwald V, Morschhauser F, et al: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Study Group. Blood 111:109-111, 2008
    • (2008) Blood , vol.111 , pp. 109-111
    • Schulz, H.1    Rehwald, V.2    Morschhauser, F.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.